{"nctId":"NCT00781950","briefTitle":"Effects of Dietary Flaxseed on Symptoms of Cardiovascular Disease in Patients With Peripheral Arterial Disease","startDateStruct":{"date":"2008-10"},"conditions":["Peripheral Arterial Disease"],"count":110,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Dietary Supplement: Placebo"]},{"label":"Flaxseed","type":"EXPERIMENTAL","interventionNames":["Dietary Supplement: Flaxseed"]}],"interventions":[{"name":"Flaxseed","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with peripheral arterial disease for more than 6 months.\n* Male or female with claudication secondary to lower extremity atherosclerotic arterial disease. (with limited IC but not incapacitated for walking on the level) confirmed with ankle/brachial pressures\\< or = to 0.9 in one or both legs) or who have had a previous intervention for peripheral arterial disease.\n* Over 40 years old\n* Able to comply with protocol requirements\n* Able to provide informed consent\n* Subjects taking anti-platelet therapy medication must be on a stable dose for 3 months prior to as well as during the study.\n* Subjects taking lipid lowering medication must be on a stable dose for 3 months prior to as well as during the study.\n\nExclusion Criteria:\n\n* Patients with ischemic rest pain in limbs, ulceration, or gangrene.\n* At baseline, any condition that prevents walking on a treadmill.\n* History of major bleeding.\n* Patients with bowel disease (including Crohn's disease, celiac disease, peptic ulcer disease, irritable bowel syndrome and diverticulosis).\n* Patients with an estimated life expectancy less than 2 years and with high baseline cardiac risk (post ischemic or diabetic cardiomyopathy with EF\\<40%, Canadian Cardiovascular Society Class 3 or 4 angina or need for coronary revascularization procedures).\n* Moderate to severe renal failure.\n* Subjects that are on supplements other that those prescribed by their clinician for the entire duration of the study.\n* Fish limitations (no more than 2 fish meals per week)\n* Gluten allergy\n* Subjects with allergies to any ingredient in the study product or placebo.\n* Patients who plan to undergo surgery during the course of the trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"100 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With All-cause Mortality, Cardiovascular Mortality, Stroke, and Myocardial Infarctions","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Effects on Exercise Performance, Blood Pressure and Circulating Lipid Levels.","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"145.6","spread":"3.4"},{"groupId":"OG001","value":"136.2","spread":"3.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.5","spread":"1.5"},{"groupId":"OG001","value":"71.8","spread":"1.7"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":52},"commonTop":["Nausea"]}}}